GET DAILY SIGNALSCoya Therapeutics (COYA) Analyst Target Points to +375% Upside
Key Takeaways
- The central stock price target of $15 is the arithmetic mean of six verified analyst price targets, rounded from an underlying average of roughly $15.33.
- That target sits far above the latest verified price near $3.16, implying an upside of about 375% — a very large move by any standard.
- The individual analyst price targets used range from a low of $12 to a high of $18, a wide spread that reflects genuine disagreement about the value of Coya's early-stage pipeline.
- The strongest supporting factor is clinical progress: enrollment is complete in the Phase 2/3 ALSTARS trial of COYA 302 in ALS, with topline data expected in early 2027.
- The biggest risks are binary trial outcomes, ongoing net losses, a shrinking cash balance, and dilution risk typical of a clinical-stage biotech.
- For more context, visit the Major News, Today's Price Move, Forecast, and Earnings pages for this ticker.
- To explore AI-driven trade ideas across the broader market, browse the Trending AI Robots.
Analyst Price Targets and Consensus View
Coya Therapeutics, Inc. (COYA), a Houston-based clinical-stage biotechnology company focused on regulatory T cell (Treg) therapies, carries a "Strong Buy" or "Moderate Buy" consensus across covering firms. I reviewed six individually attributable, current price targets: H.C. Wainwright at $18, Lake Street at $17, BTIG at $16, D. Boral Capital at $15, Chardan Capital at $14, and Roth MKM at $12. Their arithmetic mean is approximately $15.33, which rounds to the $15 central target used throughout this article. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The $12-to-$18 range is unusually wide, spanning roughly 280% to 470% above the recent price. That dispersion reflects how difficult it is to value a pre-revenue, pre-commercial biotech whose worth hinges on clinical data rather than earnings. All six firms maintain Buy-equivalent ratings, and recent actions have been reiterations rather than upgrades — a sign of steady conviction rather than new enthusiasm. Notably, an independent "Sell" designation from Weiss Ratings sits outside the numeric price-target set and is not part of the calculated average.
Current Market Position and Path Toward the Target
With shares near $3.16 following third-quarter results, reaching $15 would require a rise of roughly 375% — a very large move. The 52-week range of about $2.72 to $6.62 puts the current price toward the lower end, meaning the stock would need to climb well beyond its recent high to approach the target. From what I see, the path would almost certainly run through clinical milestones rather than fundamentals.
Coya completed enrollment in its Phase 2/3 ALSTARS trial of COYA 302 in amyotrophic lateral sclerosis (ALS), enrolling 137 participants, with topline data from the 24-week double-blind phase expected in early Q2 2027. Frontotemporal dementia (FTD) biomarker data is expected in Q1 2027. Positive data could trigger a sharp re-rating, while the same catalysts could move the stock lower if results disappoint.
What Could Support a Move Toward the Target
- COYA 302 has received Fast Track designation from the U.S. FDA in ALS, and the FDA accepted an investigational new drug (IND) application for an FTD program — signs of regulatory engagement.
- A collaboration with Dr. Reddy's Laboratories supports development and potential commercialization of COYA 302.
- The pipeline spans multiple modalities and indications, including ALS, FTD, Alzheimer's and Parkinson's disease, offering several shots on goal.
- Uniformly bullish analyst coverage suggests the firms see meaningful option value in the Treg platform despite a lack of revenue.
What Could Prevent the Target From Being Reached
- Clinical risk is binary: if ALSTARS topline data fails to show a meaningful benefit, the investment thesis could be impaired.
- Coya remains deeply unprofitable, posting a $10.6 million net loss in the most recent quarter, with collaboration revenue of only about $234,000.
- Cash and equivalents stood near $35.8 million at September 30, 2026, against rising research and development spending — raising the prospect of future equity issuance and dilution.
- The wide $12-to-$18 target range signals low confidence around any single valuation, and the stock trades near its 52-week low, reflecting weak recent sentiment.
Technical Levels and Market Structure
The shares have been in a downtrend, trading near the bottom of a 52-week range of about $2.72 to $6.62 after falling from a high near $6.62. On a technical basis, the low-$3.00 area and the recent 52-week low near $2.72 represent key support zones, while the $4.50-to-$5.00 band and the prior high near $6.62 act as major resistance. The $15 target sits far above any established resistance level, so any move toward it would require a sustained, catalyst-driven breakout rather than incremental technical progress. One thing that stands out here is how far the target sits from current technical levels.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms rarely state their precise timeframe and none guarantee the stock will reach the level. The most important upcoming items are the FTD biomarker readout expected in Q1 2027 and the ALSTARS topline data expected in early Q2 2027, followed by any financing announcements, analyst target revisions, and regulatory updates on COYA 302.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals as market conditions, technical behavior, and AI-driven analysis evolve. The tool is designed to help traders discover new opportunities, track existing positions, and identify shifting trends more efficiently than manual screening allows. For those following a volatile, catalyst-driven name such as COYA, automated signal monitoring can provide a useful complement to fundamental and technical research. I’ve found it helpful to cross-reference these signals when evaluating names like this one.
Final Assessment
The $15 central target — the rounded mean of six verified analyst price targets spanning $12 to $18 — implies a roughly 375% move from the recent price near $3.16, making it a very large and inherently low-probability near-term scenario. Support rests on clinical execution and pending data readouts, while the principal obstacles are binary trial risk, persistent losses, and a limited cash runway. Analysts broadly agree on direction but disagree sharply on magnitude, reflecting the speculative nature of the thesis. Investors should focus on the Q1 2027 FTD biomarker data and the early-Q2 2027 ALSTARS topline readout, alongside any financing developments, as the key determinants of whether COYA can build a credible path toward the target. No outcome is guaranteed.
Promo Section
In my own research process I regularly turn to Tickeron’s AI Daily Buy/Sell Signals for additional perspective on timing and trend shifts. The platform’s AI-driven alerts have helped me stay organized across a watchlist of clinical-stage names like this one, offering a practical layer alongside traditional analysis without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
COYA sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for COYA moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
COYA moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COYA crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for COYA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where COYA's RSI Oscillator exited the oversold zone, 27 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +18.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where COYA advanced for three days, in 168 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
COYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (3.498). P/E Ratio (-2.794) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. COYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement